AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives: Difference between revisions
Line 7: | Line 7: | ||
==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == | ==2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT) == | ||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit) | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' OCs may be harmful in women with additional risk factors (eg, cigarette smoking, prior thromboembolic events) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Routine screening for prothrombotic mutations before initiation of hormonal contraception is not useful. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' |<nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" style="width:80%" | {|class="wikitable" style="width:80%" | ||
|- | |- | ||
Line 12: | Line 22: | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki> Measurement of BP before initiation of hormonal contraception is recommended. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki> Measurement of BP before initiation of hormonal contraception is recommended. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki> | ||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA Guidelines Classification Scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki> Among OC users, aggressive therapy of stroke risk factors may be reasonable. ''([[ACC AHA Guidelines Classification Scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | |||
|} | |} | ||
Revision as of 15:31, 11 February 2014
Stroke Main page | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives On the Web | |
American Roentgen Ray Society Images of AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
FDA on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
CDC on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives in the news | |
Blogs on AHA/ASA guideline recommendations for prevention of stroke in women oral contraceptives | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]
Overview
2014 AHA/ASA Guideline Recommendations for Prevention of Stroke in Women (DO NOT EDIT)
Class III (No Benefit) |
"1. OCs may be harmful in women with additional risk factors (eg, cigarette smoking, prior thromboembolic events) (Level of Evidence: B) " |
"1. Routine screening for prothrombotic mutations before initiation of hormonal contraception is not useful. (Level of Evidence: A) |" |
Class I |
" Measurement of BP before initiation of hormonal contraception is recommended. (Level of Evidence: B) " |
Class IIb |
" Among OC users, aggressive therapy of stroke risk factors may be reasonable. (Level of Evidence: C)" |